SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission

NCT02270463 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
16
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Stemline Therapeutics, Inc.